U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Collaborating Centre for Mental Health (UK). Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance: Updated edition. Leicester (UK): British Psychological Society; 2014 Dec. (NICE Clinical Guidelines, No. 192.)

Cover
  • April 2018: Footnotes and cautions have been added and amended by NICE to link to the MHRA's latest advice and resources on sodium valproate. Sodium valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place. This is because of the risk of malformations and developmental abnormalities in the baby.

April 2018: Footnotes and cautions have been added and amended by NICE to link to the MHRA's latest advice and resources on sodium valproate. Sodium valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place. This is because of the risk of malformations and developmental abnormalities in the baby.

Cover of Antenatal and Postnatal Mental Health

Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance: Updated edition.

Show details

APPENDIX 17CLINICAL EVIDENCE – COMPLETED METHODOLOGY CHECKLISTS

1.1. STUDY ID

1.1.1. ADEWUYA2005 (PDF, 138K)

1.1.2. ADEWUYA2006 (PDF, 127K)

1.1.3. AGOUB2005 (PDF, 139K)

1.1.4. ALVARADO-ESQUIVEL2006 (PDF, 125K)

1.1.5. ASCASO2003 (PDF, 109K)

1.1.6. AYDIN2004 (PDF, 125K)

1.1.7. BAGGALEY2007 (PDF, 121K)

1.1.8. BARNETT1999 (PDF, 135K)

1.1.9. BECK2001 (PDF, 124K)

1.1.10. BENVENUTI1999 (PDF, 124K)

1.1.11. BERGINK2011 (PDF, 123K)

1.1.12. BERLE2003 (PDF, 122K)

1.1.13. BOYCE1993 (PDF, 124K)

1.1.14. BUNEVICIUS2009 (PDF, 122K)

1.1.15. CARPINIELLO1997 (PDF, 124K)

1.1.16. CHAUDRON2010 (PDF, 123K)

1.1.17. CHIBANDA2010 (PDF, 124K)

1.1.18. CLARKE2008 (PDF, 123K)

1.1.19. COX1987 (PDF, 126K)

1.1.20. EBERHARD-GRAN2001 (PDF, 127K)

1.1.21. EKEROMA2012 (PDF, 128K)

1.1.22. FELICE2006 (PDF, 124K)

1.1.23. FERNANDES2011 (PDF, 123K)

1.1.24. FLYNN2011 (PDF, 123K)

1.1.25. GARCIA-ESTEVE2003 (PDF, 129K)

1.1.26. GAUSIA2007 (PDF, 122K)

1.1.27. GHUBASH1997 (PDF, 121K)

1.1.28. GJERDINCJEN2009 (PDF, 124K)

1.1.29. GUEDENEY1998 (PDF, 125K)

1.1.30. HARRIS1989 (PDF, 123K)

1.1.31. JADRESIC1995 (PDF, 112K)

1.1.32. LEE1998 (PDF, 150K)

1.1.33. KADIR2004 (PDF, 122K)

1.1.34. LAU2010 (PDF, 121K)

1.1.35. LEONARDOU2009 (PDF, 123K)

1.1.36. LEVERTON2000 (PDF, 121K)

1.1.37. MAHMUD2003 (PDF, 122K)

1.1.38. MANN2012 (PDF, 129K)

1.1.39. MATTHEY2008 (PDF, 123K)

1.1.40. MAZHARI2007 (PDF, 126K)

1.1.41. MILGROM2005A (PDF, 123K)

1.1.42. MURRAY1990B (PDF, 121K)

1.1.43. MUZIK2000 (PDF, 121K)

1.1.44. PHILLIPS2009 (PDF, 128K)

1.1.45. PITANUPONG2007 (PDF, 123K)

1.1.46. REGMI2002 (PDF, 124K)

1.1.47. RUBERTSSON2011 (PDF, 126K)

1.1.48. SANTOS2007 (PDF, 124K)

1.1.49. SIDEBOTTOM2012 (PDF, 125K)

1.1.50. SMITH2010 (PDF, 126K)

1.1.51. SPIES2009 (PDF, 126K)

1.1.52. TANDON2012 (PDF, 122K)

1.1.53. TENG2005 (PDF, 122K)

1.1.54. THIAGAYSON2013 (PDF, 123K)

1.1.55. TOREKI2013 (PDF, 123K)

1.1.56. TRAN2011 (PDF, 123K)

1.1.57. UWAKWE2003 (PDF, 126K)

1.1.58. WERRETT2006 (PDF, 127K)

1.1.59. WICKBERG1996 (PDF, 125K)

1.1.60. YOSHIDA2001 (PDF, 122K)

1.3. PSYCHOSOCIAL INTERVENTIONS: PREVENTION (RISK FACTORS IDENTIFIED)

1.3.1. ARACENA2009 (PDF, 117K)

1.3.2. BARLOW2007 (PDF, 118K)

1.3.3. BARNET2007 (PDF, 118K)

1.3.4. BRUGHA2000 (PDF, 118K)

1.3.5. COOPER2009 (PDF, 117K)

1.3.6. EASTERBROOKS2013 (PDF, 118K)

1.3.7. GORMAN1997/DENNIS2013 (PDF, 118K)

1.3.8. HARRIS2006/DENNIS2013 (PDF, 118K)

1.3.9. HOWELL2012 (PDF, 117K)

1.3.10. KERSTING2013 (PDF, 117K)

1.3.11. KIEFFER2013 (PDF, 117K)

1.3.12. MEIJSSEN2010A/2010B/2011 (PDF, 118K)

1.3.13. MELNYK2006 (PDF, 117K)

1.3.14. MEYER1994 (PDF, 118K)

1.3.15. NEWNHAM2009 (PDF, 118K)

1.3.16. PHIPPS2013 (PDF, 117K)

1.3.17. RAVN2012 (PDF, 118K)

1.3.18. SEN2006/DENNIS2013 (PDF, 117K)

1.3.19. SMALL2000 /2006 (PDF, 118K)

1.3.20. SPITTLE2010/2009/SPENCERSMITH2012 (PDF, 118K)

1.3.21. STAMP1995 (PDF, 117K)

1.3.22. WEBSTER2003 (PDF, 118K)

1.4. PSYCHOSOCIAL INTERVENTIONS: PROTOCOLS FOR WOMEN FOLLOWING STILLBIRTH

1.4.1. CACCIATORE2008 (PDF, 116K)

1.4.2. GRAVENSTEEN2013 (PDF, 117K)

1.4.3. HUGHES2002/TURTON2009 (PDF, 116K)

1.4.4. RADESTAD2009/SURKAN2008 (PDF, 117K)

1.5. PSYCHOSOCIAL INTERVENTIONS: PREVENTION (NO RISK FACTORS IDENTIFIED)

1.5.1. HOWELL2014 (PDF, 117K)

1.5.2. KALINAUSKIENE2009 (PDF, 117K)

1.5.3. LAVENDER1998 (PDF, 117K)

1.5.4. MORRELL2000 (PDF, 118K)

1.5.5. MORRELL2009A/2009B/2011/BRUGHA2011 (PDF, 119K)

1.5.6. PEREZBLASCO2013 (PDF, 117K)

1.5.7. TSENG2010 (PDF, 118K)

1.6. PSYCHOSOCIAL INTERVENTIONS: TREATMENT

1.6.1. AMMERMAN2013A/2013B (PDF, 118K)

1.6.2. ARMSTRONG1999/ARMSTRONG2000/FRASER2000 (PDF, 119K)

1.6.3. ARMSTRONG2003 (PDF, 117K)

1.6.4. ARMSTRONG2004 (PDF, 117K)

1.6.5. AUSTIN2008 (PDF, 118K)

1.6.6. BERNARD2011 (PDF, 117K)

1.6.7. BILSZTA2012 (PDF, 118K)

1.6.8. BURNS2013/PEARSON2013 (PDF, 119K)

1.6.9. CHEN2000 (PDF, 117K)

1.6.10. CHO2008 (PDF, 118K)

1.6.11. COOPER2003/MURRAY2003 (PDF, 118K)

1.6.12. DENNIS2003 (PDF, 117K)

1.6.13. DENNIS2009/2010 (PDF, 118K)

1.6.14. DUGGAN2007/CALDERA2007 (PDF, 118K)

1.6.15. DUGRAVIER2013/GUEDENEY2013 (PDF, 118K)

1.6.16. ELMOHANDES2008 (PDF, 117K)

1.6.17. FIELD2013A (PDF, 118K)

1.6.18. GAMBLE2005 (PDF, 117K)

1.6.19. GAO2010/2012 (PDF, 118K)

1.6.20. GROTE2009 (PDF, 118K)

1.6.21. GUARDINO2014 (PDF, 117K)

1.6.22. HAGAN2004 (PDF, 118K)

1.6.23. HAYDEN2012 (PDF, 118K)

1.6.24. HISCOCK2002 (PDF, 117K)

1.6.25. HISCOCK2007/HISCOCK2008 (PDF, 118K)

1.6.26. HOLDEN1989 (PDF, 118K)

1.6.27. HONEY2002 (PDF, 118K)

1.6.28. HOROWITZ2001 (PDF, 117K)

1.6.29. KAAYA2013 (PDF, 117K)

1.6.30. KERSTING2011 (PDF, 117K)

1.6.31. KOZINSZKY2012 (PDF, 118K)

1.6.32. LE2011 (PDF, 117K)

1.6.33. LETOURNEAU2011 (PDF, 118K)

1.6.34. LEUNG2012 (PDF, 117K)

1.6.35. MILGROM2005B (PDF, 117K)

1.6.36. MILGROM2011A (PDF, 118K)

1.6.37. MILGROM2011B (PDF, 117K)

1.6.38. MISRI2000 (PDF, 118K)

1.6.39. MORRELL2009A/2009B/2011/BRUGHA2011 (PDF, 119K)

1.6.40. MULCAHY2010 (PDF, 118K)

1.6.41. MUNOZ2007/URIZAR2011 (PDF, 119K)

1.6.42. NEUGEBAUER2006 (PDF, 118K)

1.6.43. NIKCEVIC2007 (PDF, 117K)

1.6.44. OHARA2000 (PDF, 118K)

1.6.45. OMAHEN2013A (PDF, 117K)

1.6.46. OMAHEN2013B (PDF, 117K)

1.6.47. OMAHEN2013C (PDF, 118K)

1.6.48. ORTIZCOLLADO2014 (PDF, 118K)

1.6.49. PINHEIRO2014 (PDF, 118K)

1.6.50. PRENDERGAST2001 (PDF, 118K)

1.6.51. RAHMAN2008 (PDF, 118K)

1.6.52. ROMAN2009 (PDF, 118K)

1.6.53. ROUHE2012/SALMELAARO2012 (PDF, 118K)

1.6.54. SAISTO2001 (PDF, 117K)

1.6.55. SALOMONSSON2011 (PDF, 118K)

1.6.56. SILVERSTEIN2011 (PDF, 118K)

1.6.57. SIMAVLI2014 (PDF, 118K)

1.6.58. SLEED2013 (PDF, 117K)

1.6.59. SPINELLI2003 (PDF, 117K)

1.6.60. STEIN2006 (PDF, 118K)

1.6.61. SWANSON2009 (PDF, 118K)

1.6.62. TAMAKI2008 (PDF, 117K)

1.6.63. TANDON2011/2014/MENDELSON2013 (PDF, 119K)

1.6.64. TIMPANO2011 (PDF, 118K)

1.6.65. VANDOESUM2008/KERSTENALVAREZ2010 (PDF, 118K)

1.6.66. VIETEN2008 (PDF, 117K)

1.6.67. WEIDNER2010 (PDF, 118K)

1.6.68. WICKBERG1996 (PDF, 118K)

1.6.69. WIGGINS2005 (PDF, 118K)

1.6.70. WIKLUND2010 (PDF, 118K)

1.6.71. ZELKOWITZ2008/2011/FEELEY2012 (PDF, 118K)

1.6.72. ZLOTNICK2001 (PDF, 118K)

1.6.73. ZLOTNICK2006 (PDF, 119K)

1.6.74. ZLOTNICK2011 (PDF, 117K)

1.7. PSYCHOSOCIAL INTERVENTIONS: ALCOHOL OR SUBSTANCE MISUSE

1.7.1. STADE2009B (PDF, 106K)

1.7.2. TERPLAN2007 (PDF, 107K)

1.7.3. TURNBALL2012 (PDF, 108K)

1.8. PHARMACOLOGICAL INTERVENTIONS: PREVENTION (NO RISK FACTORS)

1.8.1. HARRISONHOHNER2001 (PDF, 117K)

1.8.2. LLORENTE2003 (PDF, 119K)

1.8.3. MAKRIDES2010 (PDF, 118K)

1.8.4. MOKHBER2011 (PDF, 117K)

1.9. PHARMACOLOGICAL INTERVENTIONS: PREVENTIONS (RISK FACTORS PRESENT)

1.9.1. HARRIS2002 (PDF, 118K)

1.9.2. LAWRIE1998B (PDF, 121K)

1.10. PHARMACOLOGICAL INTERVENTIONS: PREVENTION (PROPHYLAXIS)

1.10.1. WISNER2001 (PDF, 118K)

1.10.2. WISNER2004B (PDF, 119K)

1.11. PHARMACOLOGICAL INTERVENTIONS (TREATMENT)

1.11.1. APPLEBY1997 (PDF, 121K)

1.11.2. BLOCH2012 (PDF, 118K)

1.11.3. FREEMAN22008 (PDF, 119K)

1.11.4. GREGOIRE1996 (PDF, 118K)

1.11.5. HANTSOON2014 (PDF, 118K)

1.11.6. MOZURKEWICH2013 (PDF, 118K)

1.11.7. REES2008 (PDF, 119K)

1.11.8. SHARP2010 (PDF, 119K)

1.11.9. SU2008 (PDF, 118K)

1.11.10. WISNER2006 (PDF, 122K)

1.11.11. YONKERS2008 (PDF, 118K)

1.12. PHARMACOLOGICAL HARMS: (ANTIDEPRESSANTS)

1.12.1. BOUCHER2008 (PDF, 118K)

1.12.2. CALDERON-MARGALIT2009 (PDF, 118K)

1.12.3. CASPER2003 (PDF, 118K)

1.12.4. CHAMBERS1996 (PDF, 131K)

1.12.5. COSTEI2002 (PDF, 117K)

1.12.6. DAVIS2007 (PDF, 118K)

1.12.7. DIAV-CITRIN2008B (PDF, 118K)

1.12.8. EINARSON2009 (PDF, 118K)

1.12.9. ELMARROUN2014 (PDF, 119K)

1.12.10. FERREIRA2007 (PDF, 116K)

1.12.11. GALBALLY2009 (PDF, 118K)

1.12.12. KALLEN2004 (PDF, 118K)

1.12.13. KALLEN2007 (PDF, 118K)

1.12.14. KIELER2012 (PDF, 132K)

1.12.15. KORNUM2010 (PDF, 131K)

1.12.16. KULIN1998 (PDF, 132K)

1.12.17. LAINE2003 (PDF, 131K)

1.12.18. LEVINSONCASTIEL2006 (PDF, 132K)

1.12.19. MALM2011 (PDF, 118K)

1.12.20. MASCHI2008 (PDF, 118K)

1.12.21. OBERLANDER2006 (PDF, 118K)

1.12.22. OBERLANDER2008 (PDF, 118K)

1.12.23. PEDERSEN2009 (PDF, 118K)

1.12.24. RAMOS2008 (PDF, 119K)

1.12.25. SIMON2002 (PDF, 118K)

1.12.26. SIVOJELEZOVA2005 (PDF, 121K)

1.12.27. SURI2007 (PDF, 126K)

1.12.28. WEN2006 (PDF, 119K)

1.12.29. WICHMAN2009 (PDF, 119K)

1.12.30. WISNER009 (PDF, 118K)

1.12.31. WOGELIUS2006 (PDF, 117K)

1.13. PHARMACOLOGICAL HARMS: (ANTIPSYCHOTICS)

1.13.1. AUERBACH1992 (PDF, 118K)

1.13.2. BODEN2012A (PDF, 116K)

See 1.14.4.

1.13.3. BODEN2012B (PDF, 118K)

1.13.4. DIAV-CITRIN2005 (PDF, 119K)

1.13.5. HABERMANN2013 (PDF, 119K)

1.13.6. LIN2010 (PDF, 118K)

1.13.7. MCKENNA2005 (PDF, 125K)

1.13.8. NEWHAM2008 (PDF, 118K)

1.13.9. REIS2008 (PDF, 118K)

1.13.10. SADOWSKI2013 (PDF, 118K)

1.15. PHARMACOLOGICAL HARMS: (LITHIUM)

1.15.1. BODEN2012A (PDF, 116K)

1.15.2. CORREA-VILLASENOR1994 (PDF, 113K)

1.15.3. CZEIZEL1990 (PDF, 109K)

1.15.4. JACOBSON1992 (PDF, 119K)

1.15.5. KALLEN1983 (PDF, 117K)

1.15.6. REIS2008 (PDF, 101K)

See above

1.16. PHARMACOLOGICAL HARMS: (BENZODIAZEPINES)

1.16.1. BAN2014 (PDF, 119K)

1.16.2. CZEIZEL1987 (PDF, 112K)

1.16.3. LAEGREID1990 (PDF, 112K)

1.16.4. LAEGREID1992 (PDF, 119K)

1.16.5. LEPPE2010 (PDF, 118K)

1.16.6. OBERLANDER2008 (PDF, 119K)

1.16.7. ORNOY1998 (PDF, 118K)

1.16.8. PASTUSZAK1996 (PDF, 118K)

1.16.9. WIKNER2007 (PDF, 118K)

1.17. PHARMACOLOGICAL HARMS: (STIMULANTS)

1.17.1. POTTEGARD2014 (PDF, 124K)

1.18. PHARMACOLOGICAL INTERVENTIONS: ALCOHOL OR SUBSTANCE MISUSE

1.18.1. MINOZZI2008/2013 (PDF, 106K)

1.19

1.20. PHYSICAL INTERVENTIONS: PREVENTION (NO RISK FACTORS)

1.20.1. NORMAN2010 (PDF, 119K)

1.20.2. ROBLEDO-COLONIA2012 (PDF, 119K)

1.20.3. SONGOYGARD2012 (PDF, 118K)

1.21. PHYSICAL INTERVENTIONS: PREVENTION (RISK FACTORS IDENTIFIED)

1.21.1. HADDAD-RODRIGUES2013 (PDF, 118K)

1.22. PHYSICAL INTERVENTIONS: TREATMENT

1.22.1. ARMSTRONG2004 (PDF, 120K)

1.22.2. CHUNG2012 (PDF, 118K)

1.22.3. DALEY2008 (PDF, 120K)

1.22.4. DALEY2013 (PDF, 120K)

1.22.5. FIELD2013B (PDF, 118K)

1.22.6. MANBER2004 (PDF, 118K)

1.22.7. MANBER2010 (PDF, 119K)

1.22.8. O'HIGGINS2008 (PDF, 117K)

1.22.9. ONOZAWA2001 (PDF, 118K)

1.22.10. WIRZ-JUSTICE2011 (PDF, 117K)

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this page (5.5M)
  • PDF version of this title (8.9M)

In this Page

Other titles in this collection

Related NICE guidance and evidence

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...